P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

• Joshua D. Mitchell,
• Michael Pfeiffer,
• John Boehmer,
• John Gorcsan,
• Nalina Dronamraju,
• Stefan Faderl,
• Tara L. Lin,
• Geoffrey L. Uy,
• Jeffrey Lancet,
• Jorge Cortes

Affiliations

Joshua D. Mitchell

1 Washington University in St. Louis, Cardio-Oncology Centre of Excellence, St. Louis, United States

Michael Pfeiffer

2 Penn State Hershey Medical Center, Heart and Vascular Institute, Pennsylvania, United States

John Boehmer

2 Penn State Hershey Medical Center, Heart and Vascular Institute, Pennsylvania, United States

John Gorcsan

2 Penn State Hershey Medical Center, Heart and Vascular Institute, Pennsylvania, United States

Nalina Dronamraju

3 Jazz Pharmaceuticals, Inc., Philadelphia, United States

Stefan Faderl

4 Jazz Pharmaceuticals, Palo Alto, United States

Tara L. Lin

5 University of Kansas, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United States

Geoffrey L. Uy

6 Washington University School of Medicine, Division of Oncology, St. Louis, United States

Jeffrey Lancet

7 H. Lee Moffitt Cancer Center and Research Institute,, Tampa, United States

Jorge Cortes

8 Georgia Cancer Center, Augusta, United States